ID   AXIN1_HUMAN             Reviewed;         862 AA.
AC   O15169; Q4TT26; Q4TT27; Q86YA7; Q8WVW6; Q96S28;
DT   01-DEC-2000, integrated into UniProtKB/Swiss-Prot.
DT   10-MAY-2002, sequence version 2.
DT   22-JUL-2015, entry version 173.
DE   RecName: Full=Axin-1;
DE   AltName: Full=Axis inhibition protein 1;
DE            Short=hAxin;
GN   Name=AXIN1; Synonyms=AXIN;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=9230313; DOI=10.1016/S0092-8674(00)80324-4;
RA   Zeng L., Fagotto F., Zhang T., Hsu W., Vasicek T.J., Perry W.L. III,
RA   Lee J.J., Tilghman S.M., Gumbiner B.M., Costantini F.;
RT   "The mouse Fused locus encodes Axin, an inhibitor of the Wnt signaling
RT   pathway that regulates embryonic axis formation.";
RL   Cell 90:181-192(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=11157797; DOI=10.1093/hmg/10.4.339;
RA   Daniels R.J., Peden J.F., Lloyd C., Horsley S.W., Clark K.,
RA   Tufarelli C., Kearney L., Buckle V.J., Doggett N.A., Flint J.,
RA   Higgs D.R.;
RT   "Sequence, structure and pathology of the fully annotated terminal 2
RT   Mb of the short arm of human chromosome 16.";
RL   Hum. Mol. Genet. 10:339-352(2001).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15616553; DOI=10.1038/nature03187;
RA   Martin J., Han C., Gordon L.A., Terry A., Prabhakar S., She X.,
RA   Xie G., Hellsten U., Chan Y.M., Altherr M., Couronne O., Aerts A.,
RA   Bajorek E., Black S., Blumer H., Branscomb E., Brown N.C., Bruno W.J.,
RA   Buckingham J.M., Callen D.F., Campbell C.S., Campbell M.L.,
RA   Campbell E.W., Caoile C., Challacombe J.F., Chasteen L.A.,
RA   Chertkov O., Chi H.C., Christensen M., Clark L.M., Cohn J.D.,
RA   Denys M., Detter J.C., Dickson M., Dimitrijevic-Bussod M., Escobar J.,
RA   Fawcett J.J., Flowers D., Fotopulos D., Glavina T., Gomez M.,
RA   Gonzales E., Goodstein D., Goodwin L.A., Grady D.L., Grigoriev I.,
RA   Groza M., Hammon N., Hawkins T., Haydu L., Hildebrand C.E., Huang W.,
RA   Israni S., Jett J., Jewett P.B., Kadner K., Kimball H., Kobayashi A.,
RA   Krawczyk M.-C., Leyba T., Longmire J.L., Lopez F., Lou Y., Lowry S.,
RA   Ludeman T., Manohar C.F., Mark G.A., McMurray K.L., Meincke L.J.,
RA   Morgan J., Moyzis R.K., Mundt M.O., Munk A.C., Nandkeshwar R.D.,
RA   Pitluck S., Pollard M., Predki P., Parson-Quintana B., Ramirez L.,
RA   Rash S., Retterer J., Ricke D.O., Robinson D.L., Rodriguez A.,
RA   Salamov A., Saunders E.H., Scott D., Shough T., Stallings R.L.,
RA   Stalvey M., Sutherland R.D., Tapia R., Tesmer J.G., Thayer N.,
RA   Thompson L.S., Tice H., Torney D.C., Tran-Gyamfi M., Tsai M.,
RA   Ulanovsky L.E., Ustaszewska A., Vo N., White P.S., Williams A.L.,
RA   Wills P.L., Wu J.-R., Wu K., Yang J., DeJong P., Bruce D.,
RA   Doggett N.A., Deaven L., Schmutz J., Grimwood J., Richardson P.,
RA   Rokhsar D.S., Eichler E.E., Gilna P., Lucas S.M., Myers R.M.,
RA   Rubin E.M., Pennacchio L.A.;
RT   "The sequence and analysis of duplication-rich human chromosome 16.";
RL   Nature 432:988-994(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), AND NUCLEOTIDE
RP   SEQUENCE [LARGE SCALE MRNA] OF 471-862 (ISOFORM 1).
RC   TISSUE=Lymphoma, and Renal cell carcinoma;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   INTERACTION WITH GSK3B AND PPP2CA, PHOSPHORYLATION, AND
RP   DEPHOSPHORYLATION.
RX   PubMed=9920888; DOI=10.1074/jbc.274.6.3439;
RA   Hsu W., Zeng L., Costantini F.;
RT   "Identification of a domain of Axin that binds to the serine/threonine
RT   protein phosphatase 2A and a self-binding domain.";
RL   J. Biol. Chem. 274:3439-3445(1999).
RN   [6]
RP   DISEASE.
RX   PubMed=10700176; DOI=10.1038/73448;
RA   Satoh S., Daigo Y., Furukawa Y., Kato T., Miwa N., Nishiwaki T.,
RA   Kawasoe T., Ishiguro H., Fujita M., Tokino T., Sasaki Y., Imaoka S.,
RA   Murata M., Shimano T., Yamaoka Y., Nakamura Y.;
RT   "AXIN1 mutations in hepatocellular carcinomas, and growth suppression
RT   in cancer cells by virus-mediated transfer of AXIN1.";
RL   Nat. Genet. 24:245-250(2000).
RN   [7]
RP   INTERACTION WITH LRP5.
RX   PubMed=11336703; DOI=10.1016/S1097-2765(01)00224-6;
RA   Mao J., Wang J., Liu B., Pan W., Farr G.H. III, Flynn C., Yuan H.,
RA   Takada S., Kimelman D., Li L., Wu D.;
RT   "Low-density lipoprotein receptor-related protein-5 binds to Axin and
RT   regulates the canonical Wnt signaling pathway.";
RL   Mol. Cell 7:801-809(2001).
RN   [8]
RP   INTERACTION WITH MDFI AND MDFIC, AND FUNCTION.
RX   PubMed=12192039; DOI=10.1128/MCB.22.18.6393-6405.2002;
RA   Kusano S., Raab-Traub N.;
RT   "I-mfa domain proteins interact with Axin and affect its regulation of
RT   the Wnt and c-Jun N-terminal kinase signaling pathways.";
RL   Mol. Cell. Biol. 22:6393-6405(2002).
RN   [9]
RP   INTERACTION WITH DAB2.
RX   PubMed=12805222; DOI=10.1093/emboj/cdg286;
RA   Howe P.H.;
RT   "Regulation of the Wnt signaling pathway by disabled-2 (Dab2).";
RL   EMBO J. 22:3084-3094(2003).
RN   [10]
RP   INTERACTION WITH DIXDC1; MAP3K1 AND MAP3K4.
RX   PubMed=15262978; DOI=10.1074/jbc.M404598200;
RA   Wong C.K., Luo W., Deng Y., Zou H., Ye Z., Lin S.-C.;
RT   "The DIX domain protein coiled-coil-DIX1 inhibits c-Jun N-terminal
RT   kinase activation by Axin and dishevelled through distinct
RT   mechanisms.";
RL   J. Biol. Chem. 279:39366-39373(2004).
RN   [11]
RP   INVOLVEMENT IN CAUDAL DUPLICATION ANOMALY.
RX   PubMed=16773576; DOI=10.1086/505031;
RA   Oates N.A., van Vliet J., Duffy D.L., Kroes H.Y., Martin N.G.,
RA   Boomsma D.I., Campbell M., Coulthard M.G., Whitelaw E., Chong S.;
RT   "Increased DNA methylation at the AXIN1 gene in a monozygotic twin
RT   from a pair discordant for a caudal duplication anomaly.";
RL   Am. J. Hum. Genet. 79:155-162(2006).
RN   [12]
RP   INTERACTION WITH SMAD6; SMAD7 AND RNF111, FUNCTION, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=16601693; DOI=10.1038/sj.emboj.7601057;
RA   Liu W., Rui H., Wang J., Lin S., He Y., Chen M., Li Q., Ye Z.,
RA   Zhang S., Chan S.C., Chen Y.-G., Han J., Lin S.-C.;
RT   "Axin is a scaffold protein in TGF-beta signaling that promotes
RT   degradation of Smad7 by Arkadia.";
RL   EMBO J. 25:1646-1658(2006).
RN   [13]
RP   INTERACTION WITH DAXX, IDENTIFICATION AS A COMPONENT OF THE
RP   AXIN1-HIPK2-TP53 COMPLEX, SUBCELLULAR LOCATION, AND FUNCTION.
RX   PubMed=17210684; DOI=10.1158/0008-5472.CAN-06-1671;
RA   Li Q., Wang X., Wu X., Rui Y., Liu W., Wang J., Wang X., Liou Y.C.,
RA   Ye Z., Lin S.C.;
RT   "Daxx cooperates with the Axin/HIPK2/p53 complex to induce cell
RT   death.";
RL   Cancer Res. 67:66-74(2007).
RN   [14]
RP   PHOSPHORYLATION AT SER-75; SER-77; SER-217 AND SER-469, INTERACTION
RP   WITH GSK3B AND PPP1CA, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=17318175; DOI=10.1038/sj.emboj.7601607;
RA   Luo W., Peterson A., Garcia B.A., Coombs G., Kofahl B., Heinrich R.,
RA   Shabanowitz J., Hunt D.F., Yost H.J., Virshup D.M.;
RT   "Protein phosphatase 1 regulates assembly and function of the beta-
RT   catenin degradation complex.";
RL   EMBO J. 26:1511-1521(2007).
RN   [15]
RP   SUMOYLATION.
RX   PubMed=18632848; DOI=10.1096/fj.08-113910;
RA   Kim M.J., Chia I.V., Costantini F.;
RT   "SUMOylation target sites at the C terminus protect Axin from
RT   ubiquitination and confer protein stability.";
RL   FASEB J. 22:3785-3794(2008).
RN   [16]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [17]
RP   ADP-RIBOSYLATION, UBIQUITINATION, DOMAIN TANKYRASE-BINDING MOTIF, AND
RP   INTERACTION WITH TNKS AND TNKS2.
RX   PubMed=19759537; DOI=10.1038/nature08356;
RA   Huang S.M., Mishina Y.M., Liu S., Cheung A., Stegmeier F.,
RA   Michaud G.A., Charlat O., Wiellette E., Zhang Y., Wiessner S.,
RA   Hild M., Shi X., Wilson C.J., Mickanin C., Myer V., Fazal A.,
RA   Tomlinson R., Serluca F., Shao W., Cheng H., Shultz M., Rau C.,
RA   Schirle M., Schlegl J., Ghidelli S., Fawell S., Lu C., Curtis D.,
RA   Kirschner M.W., Lengauer C., Finan P.M., Tallarico J.A.,
RA   Bouwmeester T., Porter J.A., Bauer A., Cong F.;
RT   "Tankyrase inhibition stabilizes axin and antagonizes Wnt
RT   signalling.";
RL   Nature 461:614-620(2009).
RN   [18]
RP   UBIQUITINATION, DEUBIQUITINATION BY USP34, AND SUBCELLULAR LOCATION.
RX   PubMed=21383061; DOI=10.1128/MCB.01094-10;
RA   Lui T.T., Lacroix C., Ahmed S.M., Goldenberg S.J., Leach C.A.,
RA   Daulat A.M., Angers S.;
RT   "The Ubiquitin specific protease USP34 regulates Axin stability and
RT   Wnt/beta-catenin signaling.";
RL   Mol. Cell. Biol. 31:2053-2065(2011).
RN   [19]
RP   ADP-RIBOSYLATION, UBIQUITINATION, AND INTERACTION WITH RNF146; TNKS
RP   AND TNKS2.
RX   PubMed=21478859; DOI=10.1038/ncb2222;
RA   Zhang Y., Liu S., Mickanin C., Feng Y., Charlat O., Michaud G.A.,
RA   Schirle M., Shi X., Hild M., Bauer A., Myer V.E., Finan P.M.,
RA   Porter J.A., Huang S.M., Cong F.;
RT   "RNF146 is a poly(ADP-ribose)-directed E3 ligase that regulates axin
RT   degradation and Wnt signalling.";
RL   Nat. Cell Biol. 13:623-629(2011).
RN   [20]
RP   INTERACTION WITH TNKS, AND UBIQUITINATION.
RX   PubMed=21799911; DOI=10.1371/journal.pone.0022595;
RA   Callow M.G., Tran H., Phu L., Lau T., Lee J., Sandoval W.N., Liu P.S.,
RA   Bheddah S., Tao J., Lill J.R., Hongo J.A., Davis D., Kirkpatrick D.S.,
RA   Polakis P., Costa M.;
RT   "Ubiquitin ligase RNF146 regulates tankyrase and Axin to promote Wnt
RT   signaling.";
RL   PLoS ONE 6:E22595-E22595(2011).
RN   [21]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [22]
RP   X-RAY CRYSTALLOGRAPHY (1.57 ANGSTROMS) OF 74-220 IN COMPLEX WITH APC.
RX   PubMed=10811618; DOI=10.1093/emboj/19.10.2270;
RA   Spink K.E., Polakis P., Weis W.I.;
RT   "Structural basis of the axin-adenomatous polyposis coli
RT   interaction.";
RL   EMBO J. 19:2270-2279(2000).
RN   [23]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 383-400 IN COMPLEX WITH
RP   GSK3B.
RX   PubMed=12554650; DOI=10.1093/emboj/cdg068;
RA   Dajani R., Fraser E., Roe S.M., Yeo M., Good V.M., Thompson V.,
RA   Dale T.C., Pearl L.H.;
RT   "Structural basis for recruitment of glycogen synthase kinase 3beta to
RT   the axin-APC scaffold complex.";
RL   EMBO J. 22:494-501(2003).
RN   [24]
RP   VARIANTS HCC ARG-106; LEU-345; SER-425 AND SER-650, AND VARIANT
RP   HEPATOBLASTOMA GLN-841.
RX   PubMed=12101426; DOI=10.1038/sj.onc.1205591;
RA   Taniguchi K., Roberts L.R., Aderca I.N., Dong X., Qian C.,
RA   Murphy L.M., Nagorney D.M., Burgart L.J., Roche P.C., Smith D.I.,
RA   Ross J.A., Liu W.;
RT   "Mutational spectrum of beta-catenin, AXIN1, and AXIN2 in
RT   hepatocellular carcinomas and hepatoblastomas.";
RL   Oncogene 21:4863-4871(2002).
CC   -!- FUNCTION: Component of the beta-catenin destruction complex
CC       required for regulating CTNNB1 levels through phosphorylation and
CC       ubiquitination, and modulating Wnt-signaling. Controls
CC       dorsoventral patterning via two opposing effects; down-regulates
CC       CTNNB1 to inhibit the Wnt signaling pathway and ventralize
CC       embryos, but also dorsalizes embryos by activating a Wnt-
CC       independent JNK signaling pathway. In Wnt signaling, probably
CC       facilitates the phosphorylation of CTNNB1 and APC by GSK3B. Likely
CC       to function as a tumor suppressor. Facilitates the phosphorylation
CC       of TP53 by HIPK2 upon ultraviolet irradiation. Enhances TGF-beta
CC       signaling by recruiting the RNF111 E3 ubiquitin ligase and
CC       promoting the degradation of inhibitory SMAD7. Also component of
CC       the AXIN1-HIPK2-TP53 complex which controls cell growth, apoptosis
CC       and development. {ECO:0000269|PubMed:12192039,
CC       ECO:0000269|PubMed:16601693, ECO:0000269|PubMed:17210684}.
CC   -!- SUBUNIT: Homodimer. Interacts with ZBED3; the interaction is
CC       direct, enhanced by protein kinase GSK3B and casein kinase CSNK1E
CC       activities and decreases GSK3B-induced beta-catenin serine and
CC       threonine phosphorylations (By similarity). Component of the beta-
CC       catenin destruction complex, containing at least, CTNNB1, an axin
CC       and GSK3B, that regulates CTNNB1 protein levels through
CC       phosphorylation and ubiquitination. Interacts with CTNNB1 (via the
CC       armadillo repeats 2-7). Interacts with GSK3B; the interaction
CC       hyperphosphorylates CTNNB1 leading to its ubiquitination and
CC       destruction. Component of the AXIN1-HIPK2-TP53 complex. Interacts
CC       directly in the complex with TP53 and HIPK2. Interacts with DAXX;
CC       the interaction stimulates the interaction of DAXX with TP53,
CC       stimulates 'Ser-46' phosphorylation of TP53 and induces cell death
CC       on UV irradiation. Also binds APC, SMAD6, SMAD7 and RNF111.
CC       Interacts with DIXDC1; prevents interaction with MAP3K1. Interacts
CC       with MAP3K4. Interacts with ANKRD6 and AIDA (By similarity).
CC       Interacts with MDFI; the interaction decreases AXIN1-mediated JUN
CC       N-terminal kinase (JNK) activation. Interacts with MDFIC; the
CC       interaction inhibits beta-cateninin-mediated signaling and AXIN1-
CC       mediated JUN N-terminal kinase (JNK) activation. Interacts with
CC       LRP5 (via its phosphorylated PPPSP motifs); the interaction is
CC       stimulated by WNT1 and GSK3B and activates beta-catenin signaling.
CC       Interacts (via the C-terminal) with PPP1CA; the interaction
CC       dephosphorylates AXIN1 and regulates interaction with GSK3B.
CC       Interacts with PPP2CA; the interaction dephosphorylates AXIN1.
CC       Interacts with MACF1 (By similarity). Found in a complex composed
CC       of MACF1, APC, AXIN1, CTNNB1 and GSK3B (By similarity). Interacts
CC       with TNKS. Interacts with DAB2; the interaction is mutually
CC       exclusive with the AXIN1:PPP1CA interaction. {ECO:0000250,
CC       ECO:0000269|PubMed:10811618, ECO:0000269|PubMed:11336703,
CC       ECO:0000269|PubMed:12192039, ECO:0000269|PubMed:12554650,
CC       ECO:0000269|PubMed:12805222, ECO:0000269|PubMed:15262978,
CC       ECO:0000269|PubMed:16601693, ECO:0000269|PubMed:17210684,
CC       ECO:0000269|PubMed:17318175, ECO:0000269|PubMed:19759537,
CC       ECO:0000269|PubMed:21478859, ECO:0000269|PubMed:21799911,
CC       ECO:0000269|PubMed:9920888}.
CC   -!- INTERACTION:
CC       P39687:ANP32A; NbExp=2; IntAct=EBI-710484, EBI-359234;
CC       P70039:apc (xeno); NbExp=2; IntAct=EBI-710484, EBI-8069633;
CC       Q14194:CRMP1; NbExp=2; IntAct=EBI-710484, EBI-473101;
CC       P49674:CSNK1E; NbExp=4; IntAct=EBI-710484, EBI-749343;
CC       P35222:CTNNB1; NbExp=41; IntAct=EBI-710484, EBI-491549;
CC       Q02248:Ctnnb1 (xeno); NbExp=5; IntAct=EBI-710484, EBI-397872;
CC       Q5VWQ8-2:DAB2IP; NbExp=2; IntAct=EBI-710484, EBI-9543020;
CC       Q9UKB1:FBXW11; NbExp=4; IntAct=EBI-710484, EBI-355189;
CC       P49840:GSK3A; NbExp=2; IntAct=EBI-710484, EBI-1044067;
CC       P49841:GSK3B; NbExp=42; IntAct=EBI-710484, EBI-373586;
CC       P01106:MYC; NbExp=10; IntAct=EBI-710484, EBI-447544;
CC       P35813:PPM1A; NbExp=2; IntAct=EBI-710484, EBI-989143;
CC       P62136:PPP1CA; NbExp=4; IntAct=EBI-710484, EBI-357253;
CC       Q6ZNA4:RNF111; NbExp=2; IntAct=EBI-710484, EBI-2129175;
CC       Q99ML9:Rnf111 (xeno); NbExp=5; IntAct=EBI-710484, EBI-646015;
CC       O15105:SMAD7; NbExp=8; IntAct=EBI-710484, EBI-3861591;
CC       Q9H2K2:TNKS2; NbExp=2; IntAct=EBI-710484, EBI-4398527;
CC       P04637:TP53; NbExp=4; IntAct=EBI-710484, EBI-366083;
CC       Q14134:TRIM29; NbExp=2; IntAct=EBI-710484, EBI-702370;
CC       P23258:TUBG1; NbExp=4; IntAct=EBI-710484, EBI-302589;
CC       P46937:YAP1; NbExp=11; IntAct=EBI-710484, EBI-1044059;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Membrane {ECO:0000250}.
CC       Cell membrane {ECO:0000250}. Note=MACF1 is required for its
CC       translocation to cell membrane (By similarity). On UV irradiation,
CC       translocates to the nucleus and colocalizes with DAAX.
CC       {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=O15169-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=O15169-2; Sequence=VSP_019398;
CC   -!- TISSUE SPECIFICITY: Ubiquitously expressed.
CC   -!- DOMAIN: The tankyrase-binding motif (also named TBD) is required
CC       for interaction with tankyrase TNKS and TNKS2.
CC       {ECO:0000269|PubMed:19759537}.
CC   -!- PTM: Phosphorylation and dephosphorylation of AXIN1 regulates
CC       assembly and function of the beta-catenin complex. Phosphorylated
CC       by CK1 and GSK3B. Dephosphorylated by PPP1CA and PPP2CA.
CC       Phosphorylation by CK1 enhances binding of GSK3B to AXIN1.
CC       {ECO:0000269|PubMed:17318175, ECO:0000269|PubMed:9920888}.
CC   -!- PTM: ADP-ribosylated by tankyrase TNKS and TNKS2. Poly-ADP-
CC       ribosylated protein is recognized by RNF146, followed by
CC       ubiquitination at 'Lys-48' and subsequent activation of the Wnt
CC       signaling pathway. {ECO:0000269|PubMed:21383061}.
CC   -!- PTM: Ubiquitinated by RNF146 when poly-ADP-ribosylated, leading to
CC       its degradation and subsequent activation of the Wnt signaling
CC       pathway. Sumoylation at Lys-857 and Lys-860 prevents
CC       ubiquitination and degradation. Sumoylation is required for AXIN1-
CC       mediated JNK activation. Deubiquitinated by USP34, deubiquitinated
CC       downstream of beta-catenin stabilization step: deubiquitination is
CC       important for nuclear accumulation during Wnt signaling to
CC       positively regulate beta-catenin (CTNBB1)-mediated transcription.
CC       {ECO:0000269|PubMed:18632848, ECO:0000269|PubMed:21383061}.
CC   -!- DISEASE: Hepatocellular carcinoma (HCC) [MIM:114550]: A primary
CC       malignant neoplasm of epithelial liver cells. The major risk
CC       factors for HCC are chronic hepatitis B virus (HBV) infection,
CC       chronic hepatitis C virus (HCV) infection, prolonged dietary
CC       aflatoxin exposure, alcoholic cirrhosis, and cirrhosis due to
CC       other causes. {ECO:0000269|PubMed:12101426}. Note=The gene
CC       represented in this entry is involved in disease pathogenesis.
CC   -!- DISEASE: Caudal duplication anomaly (CADUA) [MIM:607864]: A
CC       condition characterized by the occurrence of duplications of
CC       different organs in the caudal region.
CC       {ECO:0000269|PubMed:16773576}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry. Caudal
CC       duplication anomaly is associated with hypermethylation of the
CC       AXIN1 promoter.
CC   -!- SIMILARITY: Contains 1 DIX domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00069}.
CC   -!- SIMILARITY: Contains 1 RGS domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00171}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAC51624.1; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/AXIN1ID379ch16p13.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF009674; AAC51624.1; ALT_INIT; mRNA.
DR   EMBL; AE006463; AAK61224.1; -; Genomic_DNA.
DR   EMBL; Z69667; CAI95589.2; -; Genomic_DNA.
DR   EMBL; AC005202; CAI95589.2; JOINED; Genomic_DNA.
DR   EMBL; Z99754; CAI95589.2; JOINED; Genomic_DNA.
DR   EMBL; Z69667; CAI95590.2; -; Genomic_DNA.
DR   EMBL; AC005202; CAI95590.2; JOINED; Genomic_DNA.
DR   EMBL; Z99754; CAI95590.2; JOINED; Genomic_DNA.
DR   EMBL; Z99754; CAI95600.2; -; Genomic_DNA.
DR   EMBL; AC005202; CAI95600.2; JOINED; Genomic_DNA.
DR   EMBL; Z69667; CAI95600.2; JOINED; Genomic_DNA.
DR   EMBL; Z99754; CAI95601.2; -; Genomic_DNA.
DR   EMBL; AC005202; CAI95601.2; JOINED; Genomic_DNA.
DR   EMBL; Z69667; CAI95601.2; JOINED; Genomic_DNA.
DR   EMBL; BC017447; AAH17447.1; -; mRNA.
DR   EMBL; BC044648; AAH44648.1; -; mRNA.
DR   CCDS; CCDS10405.1; -. [O15169-1]
DR   CCDS; CCDS10406.1; -. [O15169-2]
DR   RefSeq; NP_003493.1; NM_003502.3. [O15169-1]
DR   RefSeq; NP_851393.1; NM_181050.2. [O15169-2]
DR   UniGene; Hs.592082; -.
DR   PDB; 1DK8; X-ray; 1.57 A; A=74-220.
DR   PDB; 1EMU; X-ray; 1.90 A; A=80-211.
DR   PDB; 1O9U; X-ray; 2.40 A; B=383-400.
DR   PDB; 3ZDI; X-ray; 2.64 A; B=383-400.
DR   PDB; 4B7T; X-ray; 2.77 A; B=383-400.
DR   PDB; 4NM0; X-ray; 2.50 A; B=383-402.
DR   PDB; 4NM3; X-ray; 2.10 A; B=383-402.
DR   PDB; 4NM5; X-ray; 2.30 A; B=383-402.
DR   PDB; 4NM7; X-ray; 2.30 A; B=383-402.
DR   PDB; 4NU1; X-ray; 2.50 A; B=383-402.
DR   PDBsum; 1DK8; -.
DR   PDBsum; 1EMU; -.
DR   PDBsum; 1O9U; -.
DR   PDBsum; 3ZDI; -.
DR   PDBsum; 4B7T; -.
DR   PDBsum; 4NM0; -.
DR   PDBsum; 4NM3; -.
DR   PDBsum; 4NM5; -.
DR   PDBsum; 4NM7; -.
DR   PDBsum; 4NU1; -.
DR   ProteinModelPortal; O15169; -.
DR   SMR; O15169; 74-220, 779-862.
DR   BioGrid; 113909; 56.
DR   DIP; DIP-34630N; -.
DR   IntAct; O15169; 66.
DR   MINT; MINT-100969; -.
DR   STRING; 9606.ENSP00000262320; -.
DR   ChEMBL; CHEMBL3038464; -.
DR   PhosphoSite; O15169; -.
DR   BioMuta; AXIN1; -.
DR   MaxQB; O15169; -.
DR   PaxDb; O15169; -.
DR   PRIDE; O15169; -.
DR   Ensembl; ENST00000262320; ENSP00000262320; ENSG00000103126.
DR   Ensembl; ENST00000354866; ENSP00000346935; ENSG00000103126. [O15169-2]
DR   GeneID; 8312; -.
DR   KEGG; hsa:8312; -.
DR   UCSC; uc002cgp.2; human. [O15169-1]
DR   UCSC; uc002cgq.2; human. [O15169-2]
DR   CTD; 8312; -.
DR   GeneCards; GC16M000338; -.
DR   HGNC; HGNC:903; AXIN1.
DR   HPA; CAB012987; -.
DR   HPA; HPA042412; -.
DR   MIM; 114550; phenotype.
DR   MIM; 603816; gene.
DR   MIM; 607864; phenotype.
DR   neXtProt; NX_O15169; -.
DR   PharmGKB; PA25195; -.
DR   eggNOG; NOG238205; -.
DR   GeneTree; ENSGT00390000010011; -.
DR   HOVERGEN; HBG004324; -.
DR   InParanoid; O15169; -.
DR   KO; K02157; -.
DR   OMA; WHHFPPR; -.
DR   OrthoDB; EOG79PJQ0; -.
DR   PhylomeDB; O15169; -.
DR   TreeFam; TF315454; -.
DR   Reactome; REACT_11063; Degradation of beta-catenin by the destruction complex.
DR   Reactome; REACT_11065; Beta-catenin phosphorylation cascade.
DR   Reactome; REACT_263873; degradation of AXIN.
DR   Reactome; REACT_263893; truncations of AMER1 destabilize the destruction complex.
DR   Reactome; REACT_263992; APC truncation mutants have impaired AXIN binding.
DR   Reactome; REACT_264030; AXIN missense mutants destabilize the destruction complex.
DR   Reactome; REACT_264034; disassembly of the destruction complex and recruitment of AXIN to the membrane.
DR   Reactome; REACT_264092; misspliced GSK3beta mutants stabilize beta-catenin.
DR   Reactome; REACT_264127; T41 mutants of beta-catenin aren't phosphorylated.
DR   Reactome; REACT_264295; S45 mutants of beta-catenin aren't phosphorylated.
DR   Reactome; REACT_264581; S33 mutants of beta-catenin aren't phosphorylated.
DR   Reactome; REACT_264596; TCF dependent signaling in response to WNT.
DR   Reactome; REACT_264636; S37 mutants of beta-catenin aren't phosphorylated.
DR   SignaLink; O15169; -.
DR   EvolutionaryTrace; O15169; -.
DR   GeneWiki; AXIN1; -.
DR   GenomeRNAi; 8312; -.
DR   NextBio; 31127; -.
DR   PRO; PR:O15169; -.
DR   Proteomes; UP000005640; Chromosome 16.
DR   Bgee; O15169; -.
DR   CleanEx; HS_AXIN1; -.
DR   ExpressionAtlas; O15169; baseline and differential.
DR   Genevisible; O15169; HS.
DR   GO; GO:0030877; C:beta-catenin destruction complex; IDA:UniProtKB.
DR   GO; GO:0005938; C:cell cortex; IBA:GO_Central.
DR   GO; GO:0071944; C:cell periphery; IDA:BHF-UCL.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0016023; C:cytoplasmic membrane-bounded vesicle; IBA:GO_Central.
DR   GO; GO:0005881; C:cytoplasmic microtubule; IBA:GO_Central.
DR   GO; GO:0031410; C:cytoplasmic vesicle; ISS:BHF-UCL.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0016328; C:lateral plasma membrane; IDA:MGI.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:BHF-UCL.
DR   GO; GO:0005886; C:plasma membrane; IBA:GO_Central.
DR   GO; GO:0014069; C:postsynaptic density; IBA:GO_Central.
DR   GO; GO:0070016; F:armadillo repeat domain binding; ISS:BHF-UCL.
DR   GO; GO:0008013; F:beta-catenin binding; IDA:BHF-UCL.
DR   GO; GO:0019899; F:enzyme binding; IPI:UniProtKB.
DR   GO; GO:0005096; F:GTPase activator activity; IBA:GO_Central.
DR   GO; GO:0070411; F:I-SMAD binding; IPI:BHF-UCL.
DR   GO; GO:0042802; F:identical protein binding; ISS:BHF-UCL.
DR   GO; GO:0032947; F:protein complex scaffold; IDA:BHF-UCL.
DR   GO; GO:0042803; F:protein homodimerization activity; ISS:UniProtKB.
DR   GO; GO:0019901; F:protein kinase binding; ISS:BHF-UCL.
DR   GO; GO:0004871; F:signal transducer activity; IDA:BHF-UCL.
DR   GO; GO:0046332; F:SMAD binding; IPI:BHF-UCL.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; IPI:UniProtKB.
DR   GO; GO:0007257; P:activation of JUN kinase activity; IBA:GO_Central.
DR   GO; GO:0032147; P:activation of protein kinase activity; IDA:BHF-UCL.
DR   GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW.
DR   GO; GO:0048320; P:axial mesoderm formation; IBA:GO_Central.
DR   GO; GO:0060070; P:canonical Wnt signaling pathway; IC:UniProtKB.
DR   GO; GO:0060823; P:canonical Wnt signaling pathway involved in neural plate anterior/posterior pattern formation; IBA:GO_Central.
DR   GO; GO:0008219; P:cell death; IBA:GO_Central.
DR   GO; GO:0030154; P:cell differentiation; IBA:GO_Central.
DR   GO; GO:0043623; P:cellular protein complex assembly; IDA:BHF-UCL.
DR   GO; GO:0071407; P:cellular response to organic cyclic compound; IBA:GO_Central.
DR   GO; GO:0031122; P:cytoplasmic microtubule organization; IBA:GO_Central.
DR   GO; GO:0007368; P:determination of left/right symmetry; IBA:GO_Central.
DR   GO; GO:0009950; P:dorsal/ventral axis specification; IBA:GO_Central.
DR   GO; GO:0048048; P:embryonic eye morphogenesis; IBA:GO_Central.
DR   GO; GO:0060272; P:embryonic skeletal joint morphogenesis; IBA:GO_Central.
DR   GO; GO:0021797; P:forebrain anterior/posterior pattern specification; IBA:GO_Central.
DR   GO; GO:0071514; P:genetic imprinting; IEA:Ensembl.
DR   GO; GO:0001701; P:in utero embryonic development; IEA:Ensembl.
DR   GO; GO:0055001; P:muscle cell development; IBA:GO_Central.
DR   GO; GO:0090090; P:negative regulation of canonical Wnt signaling pathway; IBA:GO_Central.
DR   GO; GO:0045599; P:negative regulation of fat cell differentiation; IBA:GO_Central.
DR   GO; GO:0051248; P:negative regulation of protein metabolic process; IEA:Ensembl.
DR   GO; GO:0034244; P:negative regulation of transcription elongation from RNA polymerase II promoter; IBA:GO_Central.
DR   GO; GO:0030178; P:negative regulation of Wnt signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0006913; P:nucleocytoplasmic transport; IEA:Ensembl.
DR   GO; GO:0030910; P:olfactory placode formation; IBA:GO_Central.
DR   GO; GO:0001743; P:optic placode formation; IBA:GO_Central.
DR   GO; GO:0090263; P:positive regulation of canonical Wnt signaling pathway; TAS:Reactome.
DR   GO; GO:0043547; P:positive regulation of GTPase activity; IBA:GOC.
DR   GO; GO:0046330; P:positive regulation of JNK cascade; ISS:UniProtKB.
DR   GO; GO:0033138; P:positive regulation of peptidyl-serine phosphorylation; NAS:BHF-UCL.
DR   GO; GO:0010800; P:positive regulation of peptidyl-threonine phosphorylation; NAS:BHF-UCL.
DR   GO; GO:0032436; P:positive regulation of proteasomal ubiquitin-dependent protein catabolic process; IEA:Ensembl.
DR   GO; GO:0045732; P:positive regulation of protein catabolic process; IDA:BHF-UCL.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0031398; P:positive regulation of protein ubiquitination; NAS:BHF-UCL.
DR   GO; GO:2000060; P:positive regulation of protein ubiquitination involved in ubiquitin-dependent protein catabolic process; ISS:BHF-UCL.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IMP:BHF-UCL.
DR   GO; GO:0030511; P:positive regulation of transforming growth factor beta receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0051443; P:positive regulation of ubiquitin-protein transferase activity; IMP:BHF-UCL.
DR   GO; GO:0036342; P:post-anal tail morphogenesis; IEA:Ensembl.
DR   GO; GO:0030163; P:protein catabolic process; IEA:Ensembl.
DR   GO; GO:0051260; P:protein homooligomerization; IEA:Ensembl.
DR   GO; GO:0000209; P:protein polyubiquitination; IEA:Ensembl.
DR   GO; GO:0035412; P:regulation of catenin import into nucleus; IBA:GO_Central.
DR   GO; GO:0007605; P:sensory perception of sound; IEA:Ensembl.
DR   GO; GO:0038032; P:termination of G-protein coupled receptor signaling pathway; IEA:InterPro.
DR   GO; GO:0090244; P:Wnt signaling pathway involved in somitogenesis; IBA:GO_Central.
DR   GO; GO:0021881; P:Wnt-activated signaling pathway involved in forebrain neuron fate commitment; IBA:GO_Central.
DR   Gene3D; 1.10.196.10; -; 2.
DR   InterPro; IPR029797; AXIN1.
DR   InterPro; IPR014936; Axin_b-cat-bd.
DR   InterPro; IPR001158; DIX.
DR   InterPro; IPR016137; RGS.
DR   InterPro; IPR024066; RGS_subdom1.
DR   InterPro; IPR029071; Ubiquitin-rel_dom.
DR   PANTHER; PTHR10845:SF11; PTHR10845:SF11; 1.
DR   Pfam; PF08833; Axin_b-cat_bind; 1.
DR   Pfam; PF00778; DIX; 1.
DR   Pfam; PF00615; RGS; 1.
DR   PRINTS; PR01301; RGSPROTEIN.
DR   SMART; SM00021; DAX; 1.
DR   SMART; SM00315; RGS; 1.
DR   SUPFAM; SSF48097; SSF48097; 1.
DR   SUPFAM; SSF54236; SSF54236; 1.
DR   PROSITE; PS50841; DIX; 1.
DR   PROSITE; PS50132; RGS; 1.
PE   1: Evidence at protein level;
KW   3D-structure; ADP-ribosylation; Alternative splicing; Apoptosis;
KW   Cell membrane; Complete proteome; Cytoplasm; Developmental protein;
KW   Disease mutation; Isopeptide bond; Membrane; Nucleus; Phosphoprotein;
KW   Reference proteome; Tumor suppressor; Ubl conjugation;
KW   Wnt signaling pathway.
FT   CHAIN         1    862       Axin-1.
FT                                /FTId=PRO_0000220888.
FT   DOMAIN       88    211       RGS. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00171}.
FT   DOMAIN      780    862       DIX. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00069}.
FT   REGION      209    338       Interaction with TP53. {ECO:0000250}.
FT   REGION      348    433       Interaction with GSK3B. {ECO:0000250}.
FT   REGION      434    502       Interaction with CTNNB1. {ECO:0000250}.
FT   REGION      507    757       Interaction with RNF111.
FT   REGION      575    789       Interaction with PPP2CA.
FT   REGION      677    752       Interaction with HIPK2. {ECO:0000250}.
FT   MOTIF        20     29       Tankyrase-binding motif.
FT   MOD_RES      75     75       Phosphoserine; by CK1.
FT                                {ECO:0000269|PubMed:17318175}.
FT   MOD_RES      77     77       Phosphoserine; by CK1.
FT                                {ECO:0000269|PubMed:17318175}.
FT   MOD_RES     217    217       Phosphoserine; by CK1.
FT                                {ECO:0000269|PubMed:17318175}.
FT   MOD_RES     469    469       Phosphoserine; by CK1.
FT                                {ECO:0000269|PubMed:17318175}.
FT   MOD_RES     481    481       Phosphothreonine; by GSK3-beta.
FT                                {ECO:0000305|PubMed:9920888}.
FT   MOD_RES     486    486       Phosphoserine; by GSK3-beta.
FT                                {ECO:0000250}.
FT   MOD_RES     493    493       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:O35625}.
FT   CROSSLNK    857    857       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO).
FT                                {ECO:0000250}.
FT   CROSSLNK    860    860       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO).
FT                                {ECO:0000250}.
FT   VAR_SEQ     730    765       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_019398.
FT   VARIANT     106    106       L -> R (in HCC).
FT                                {ECO:0000269|PubMed:12101426}.
FT                                /FTId=VAR_015589.
FT   VARIANT     345    345       P -> L (in HCC).
FT                                {ECO:0000269|PubMed:12101426}.
FT                                /FTId=VAR_015590.
FT   VARIANT     425    425       G -> S (in HCC; dbSNP:rs116350678).
FT                                {ECO:0000269|PubMed:12101426}.
FT                                /FTId=VAR_015591.
FT   VARIANT     650    650       G -> S (in HCC and in hepatoblastoma;
FT                                dbSNP:rs117208012).
FT                                {ECO:0000269|PubMed:12101426}.
FT                                /FTId=VAR_015592.
FT   VARIANT     841    841       R -> Q (in hepatoblastoma;
FT                                dbSNP:rs34015754).
FT                                {ECO:0000269|PubMed:12101426}.
FT                                /FTId=VAR_015593.
FT   CONFLICT    360    360       V -> A (in Ref. 1; AAC51624).
FT                                {ECO:0000305}.
FT   CONFLICT    451    455       CVDMG -> LCWTWA (in Ref. 1; AAC51624).
FT                                {ECO:0000305}.
FT   CONFLICT    482    482       P -> T (in Ref. 1; AAC51624).
FT                                {ECO:0000305}.
FT   HELIX        81     87       {ECO:0000244|PDB:1DK8}.
FT   HELIX        89     92       {ECO:0000244|PDB:1DK8}.
FT   HELIX        96    107       {ECO:0000244|PDB:1DK8}.
FT   TURN        108    110       {ECO:0000244|PDB:1DK8}.
FT   HELIX       112    126       {ECO:0000244|PDB:1DK8}.
FT   HELIX       131    133       {ECO:0000244|PDB:1EMU}.
FT   HELIX       134    148       {ECO:0000244|PDB:1DK8}.
FT   HELIX       155    159       {ECO:0000244|PDB:1DK8}.
FT   HELIX       162    174       {ECO:0000244|PDB:1DK8}.
FT   TURN        179    182       {ECO:0000244|PDB:1DK8}.
FT   HELIX       183    195       {ECO:0000244|PDB:1DK8}.
FT   HELIX       197    201       {ECO:0000244|PDB:1DK8}.
FT   HELIX       205    208       {ECO:0000244|PDB:1DK8}.
FT   TURN        209    212       {ECO:0000244|PDB:1DK8}.
FT   HELIX       385    400       {ECO:0000244|PDB:4NM3}.
SQ   SEQUENCE   862 AA;  95635 MW;  10779173F5092F3F CRC64;
     MNIQEQGFPL DLGASFTEDA PRPPVPGEEG ELVSTDPRPA SYSFCSGKGV GIKGETSTAT
     PRRSDLDLGY EPEGSASPTP PYLKWAESLH SLLDDQDGIS LFRTFLKQEG CADLLDFWFA
     CTGFRKLEPC DSNEEKRLKL ARAIYRKYIL DNNGIVSRQT KPATKSFIKG CIMKQLIDPA
     MFDQAQTEIQ ATMEENTYPS FLKSDIYLEY TRTGSESPKV CSDQSSGSGT GKGISGYLPT
     LNEDEEWKCD QDMDEDDGRD AAPPGRLPQK LLLETAAPRV SSSRRYSEGR EFRYGSWREP
     VNPYYVNAGY ALAPATSAND SEQQSLSSDA DTLSLTDSSV DGIPPYRIRK QHRREMQESV
     QVNGRVPLPH IPRTYRVPKE VRVEPQKFAE ELIHRLEAVQ RTREAEEKLE ERLKRVRMEE
     EGEDGDPSSG PPGPCHKLPP APAWHHFPPR CVDMGCAGLR DAHEENPESI LDEHVQRVLR
     TPGRQSPGPG HRSPDSGHVA KMPVALGGAA SGHGKHVPKS GAKLDAAGLH HHRHVHHHVH
     HSTARPKEQV EAEATRRAQS SFAWGLEPHS HGARSRGYSE SVGAAPNASD GLAHSGKVGV
     ACKRNAKKAE SGKSASTEVP GASEDAEKNQ KIMQWIIEGE KEISRHRRTG HGSSGTRKPQ
     PHENSRPLSL EHPWAGPQLR TSVQPSHLFI QDPTMPPHPA PNPLTQLEEA RRRLEEEEKR
     ASRAPSKQRY VQEVMRRGRA CVRPACAPVL HVVPAVSDME LSETETRSQR KVGGGSAQPC
     DSIVVAYYFC GEPIPYRTLV RGRAVTLGQF KELLTKKGSY RYYFKKVSDE FDCGVVFEEV
     REDEAVLPVF EEKIIGKVEK VD
//
